{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:00:18Z","timestamp":1776117618482,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069419"],"award-info":[{"award-number":["UM1 AI069419"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127028","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:46:18Z","timestamp":1743097578000},"page":"127028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV"],"prefix":"10.1016","volume":"55","author":[{"given":"Minhee","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.127028_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127028_bb0010","series-title":"Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics (Guidance for Industry)","author":"Food and Drug Administration Center for Drug Evaluation and Research","year":"2022"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127028_bb0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Adaptive Platform Trials, C","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127028_bb0020","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s43441-021-00315-7","article-title":"Practical considerations and recommendations for master protocol framework: basket, umbrella and platform Trials","volume":"55","author":"Lu","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127028_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2307\/2983471","article-title":"Multiplicity Considerations in the Design and Analysis of Clinical Trials","volume":"159","author":"Cook","year":"1996","journal-title":"Journal of the Royal Statistical Society. Series A (Statistics in Society)"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127028_bb0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/sim.4780100609","article-title":"Multiple testing in clinical trials","volume":"10","author":"Bauer","year":"1991","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127028_bb0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2307\/2531158","article-title":"Procedures for comparing samples with multiple endpoints","volume":"40","author":"O\u2019Brien","year":"1984","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127028_bb0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2307\/2531989","article-title":"The analysis of multiple endpoints in clinical trials","volume":"43","author":"Pocock","year":"1987","journal-title":"Biometrics"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127028_bb0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMra1709701","article-title":"Multiplicity considerations in clinical Trials","volume":"378","author":"Dmitrienko","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127028_bb0050","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J","article-title":"Some comments on frequently used multiple endpoint adjustment methods in clinical trials","volume":"16","author":"Sankoh","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2025.127028_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106656","article-title":"Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: clear guidance is needed","volume":"113","author":"Molloy","year":"2022","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127028_bb0060","first-page":"746","article-title":"An introduction to multiplicity issues in clinical trials: the what, why, when and how","volume":"46","author":"Li","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127028_bb0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0197-2456(00)00106-9","article-title":"Practical guidelines for multiplicity adjustment in clinical trials","volume":"21","author":"Proschan","year":"2000","journal-title":"Control Clin Trials"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127028_bb0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2025.127028_bb0075","series-title":"Group sequential methods with applications to clinical trials","author":"Jennison","year":"1999"},{"issue":"526","key":"10.1016\/j.vaccine.2025.127028_bb0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment","volume":"44","author":"Haybittle","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.vaccine.2025.127028_bb0085","first-page":"5","article-title":"Multiplicity in clinical trials. Encyclopedia of","author":"Hughes","year":"2005","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127028_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/sim.3748","article-title":"Hierarchical testing of multiple endpoints in group-sequential trials","volume":"29","author":"Glimm","year":"2010","journal-title":"Stat Med"},{"issue":"13\u201314","key":"10.1016\/j.vaccine.2025.127028_bb0095","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/sim.4780131320","article-title":"Monitoring multi-armed trials","volume":"13","author":"Proschan","year":"1994","journal-title":"Stat Med"},{"issue":"28","key":"10.1016\/j.vaccine.2025.127028_bb0100","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/sim.9580","article-title":"Group sequential methods for interim monitoring of randomized clinical trials with time-lagged outcome","volume":"41","author":"Tsiatis","year":"2022","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127028_bb0105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127028_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cid\/cir270","article-title":"Hepatitis B and the need for a booster dose","volume":"53","author":"Leuridan","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127028_bb0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciad201","article-title":"Immunogenicity and safety of hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HEPLISAV-B) in HBV vaccine-naive people with HIV","volume":"77","author":"Marks","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127028_bb0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127028_bb0125","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0264-410X(96)00062-X","article-title":"Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination","volume":"14","author":"West","year":"1996","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127028_bb0130","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"9349","key":"10.1016\/j.vaccine.2025.127028_bb0135","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127028_bb0140","first-page":"509","article-title":"Insufficient response to hepatitis B vaccination in HIV-positive homosexual men","volume":"6","author":"Keet","year":"1992","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127028_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004836-199201000-00007","article-title":"Impaired response to recombinant hepatitis B vaccine in HIV-infected persons","volume":"14","author":"Bruguera","year":"1992","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127028_bb0150","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1080\/21645515.2015.1055424","article-title":"Hepatitis B and a vaccination in HIV-infected adults: a review","volume":"11","author":"Mena","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127028_bb0155","article-title":"Immune responses to HBV vaccine in people living with HIV (PLWHs) who achieved successful treatment: a prospective cohort study","volume":"11","author":"Xu","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"19","key":"10.1016\/j.vaccine.2025.127028_bb0160","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127028_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062074","article-title":"Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients","volume":"8","author":"Winckelmann","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127028_bb0170","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127028_bb0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10543406.2011.550111","article-title":"Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation","volume":"21","author":"Li","year":"2011","journal-title":"J Biopharm Stat"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127028_bb0180","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciad201","article-title":"Immunogenicity and safety of hepatitis B virus (HBV) vaccine with a toll-like receptor 9 agonist adjuvant in HBV vaccine-naive people with human immunodeficiency virus","volume":"77","author":"Marks","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127028_bb0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.127028_bb0190","series-title":"Food and drug administration center for drug evaluation and research, guidance for industry: Non-inferiority clinical Trials to establish effectiveness","year":"2016"},{"key":"10.1016\/j.vaccine.2025.127028_bb0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"issue":"34","key":"10.1016\/j.vaccine.2025.127028_bb0200","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1016\/j.vaccine.2010.06.030","article-title":"Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220","volume":"28","author":"Overton","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127028_bb0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1740774510369019","article-title":"A general inefficacy interim monitoring rule for randomized clinical trials","volume":"7","author":"Freidlin","year":"2010","journal-title":"Clin Trials"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127028_bb0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/19466315.2021.1906743","article-title":"Type I error considerations in master protocols with common control in oncology Trials: report of an American Statistical Association biopharmaceutical section open forum discussion","volume":"14","author":"Sridhara","year":"2022","journal-title":"Statistics in Biopharmaceutical Research"},{"key":"10.1016\/j.vaccine.2025.127028_bb0215","first-page":"15","article-title":"Adjustment on the type I error rate for a clinical trial monitoring for both intermediate and primary endpoints","volume":"7","author":"Halabi","year":"2012","journal-title":"J Biom Biostat"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127028_bb0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs conventional Trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9940","key":"10.1016\/j.vaccine.2025.127028_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(14)61122-3","article-title":"More multiarm randomised trials of superiority are needed","volume":"384","author":"Parmar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127028_bb0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12885-020-6525-0","article-title":"A web application for the design of multi-arm clinical trials","volume":"20","author":"Grayling","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2025.127028_bb0235","article-title":"Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis","volume":"377","author":"Williams","year":"2022","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:09:49Z","timestamp":1762456189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25003251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"alternative-id":["S0264410X25003251"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127028"}}